Glaxo to reveal HIV hope
Sunday 26 January 1997
However, the findings are being treated with caution by some researchers, who fear the rise in cocktail treatments - combinations of two or more drugs to treat HIV, the virus that causes Aids - brings pitfalls.
Glaxo Wellcome, in conjunction with its partner Vertex, a US biotechnology company listed on the Nasdaq stock exchange, will announce results for a combination treatment of two protease inhibitor compounds developed by Vertex.
The paper will describe the effect of using 1592U89 and 141W494 on a a small group of Aids patients. Seven were tested, and it is understood that while two withdrew from the trial because of side-effects the other five had virus levels reduced to undetectable.
The news follows hard on an announcement on Friday for a combination of Glaxo's 3TC and Bristol-Myers Squibb's d4T, which could also reduce HIV in some patients' blood to undetectable levels. But if the patient had previously used a combination of Glaxo's 3TC and its AZT, the new treatment caused a drop of only 50 per cent - not enough, it is believed, to make much difference to the patient's health.
So-called cocktail therapies have proved to be highly promising ways of treating patients. But the conference has also noted that their proliferation will make them more difficult to track, with each new combination needing more and more analysis to show which is the most effective at different stages of the disease.
If a doctor prescribes the wrong drugs, or gives them to a patient in the wrong order, he risks leaving the patient defenceless farther down the road.
"Each choice minimises your future," said Harvard researcher Dr Cal Cohen. "If a doctor guesses wrong, then you're done with plan B and plan A, and have fewer choices for plan C."
Robert Frost, director of the American Foundation for Aids Research, warned of "the growing concern that the order in which we use combinations of drugs will affect therapeutic options in the future".
Because of the ability of HIV to mutate, many Aids patients are now resistant to older treatments, such as Glaxo's AZT.
The sombre note will temper the optimism of the Glaxo findings, which analysts are unconvinced signal any significant impact yet on the company's profitability. Glaxo, though, is desperate to find replacements as fast as it can for its billion-dollar ulcer drug Zantac, sales of which have been hit badly by coming off patent in the US.
- 1 BBC told new political editor must be 'impartial' with Nick Robinson reportedly stepping down
- 2 Number of young homeless people in Britain is 'more than three times the official figures'
- 3 Humans of New York image of crying gay teen receives best response yet from Ellen DeGeneres
- 4 The map showing the most dangerous tourist destinations in Europe, according to the Foreign Office
- 5 Swedish minister gives strongest case yet on why EU should stop turning away asylum seekers
More Britons believe that multiculturalism makes the country worse - not better, says poll
Nathan Collier: Montana man inspired by same-sex marriage ruling requests right to wed two wives
Greece crisis: IMF was pushed around by Angela Merkel and Nicholas Sarkozy – and now it is being humiliated
Forget little green men – aliens will look like humans, says Cambridge University evolution expert
Girl, 7, stares down hate preacher at Ohio festival with pro-LGBT rainbow flag gesture
Osborne to cap family benefits at £23,000 – announced ahead of his post-election Budget
iJobs Money & Business
£15000 - £17000 per annum: Recruitment Genius: This company offers a range of ...
£15000 - £16000 per annum: Recruitment Genius: Customer Service Advisors are r...
£20000 - £25000 per annum + OTE £45K: SThree: SThree were established in 1986....
£40000 - £60000 per annum: Recruitment Genius: A Compliance Manager is require...